Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

NCT06408857 | Recruiting Phase 1 DMC

• 1 other identifier: Gates MRI-MAM01-103
• Study Type: interventional
• Target: 123
• Locations: 1 country
• Sites: 2

Brief Summary

This study will test a new drug (MAM01) to find which doses are safe and could help prevent people from getting malaria for at least 4 months. The study will take place in parts of Africa where malaria is common. Part A is an open-label study conducted in healthy adults whereas Part B is double-blind study conducted in young children and infants. Both the parts will evaluate the safety, tolerability and pharmacokinetics of MAM01.

Conditions

Healthy Volunteers

Keywords

Malaria; Plasmodium falciparum; MAM01; De-Escalation; Dose Escalation; Perennial Malaria Transmission; Antibody; Monoclonal; Prevention; Pediatric; mAb-1797

Outcome Measures

Primary Outcomes (4)

• Number of participants reporting Treatment-emergent adverse events (TEAEs)

  Up to 28 days post dose (Part A and B)

• Number of participants reporting serious adverse events (SAEs), adverse events of special interest (AESI), and AEs leading to discontinuation

  Up to 182 days post dose

• Number of participants reporting solicited systemic AEs and solicited injection site AEs (applicable to IM dosing)

  Up to 7 days post dose

• Number of participants reporting solicited systemic AEs and solicited injection site AEs (applicable to SC dosing)

  Up to 7 days post dose

Secondary Outcomes (5)

• Percentage of participants with graded abnormal clinical hematology and chemistry laboratory results

  Up to 28 days post dose

• Maximal observed blood concentration of MAM01 following the first dose (Cmax1)

  Pre- and post-dose (IV dosing groups only) at Day 1, 4, 7, 14, 28, 56, 84, 112, 140, and 182

• Concentration at Day 182 (C182)

  At Day 182 post first dose

• Total Area Under the Concentration Curve (AUC) Day 0 - Day 182

  From 0 to 182 days post dose

• Percentage of participants with antidrug antibodies (ADAs) to MAM01

  At Days 1, 28, 84, and 182

Study Arms (11)

Part A: Cohort 1a (Healthy Adults): 300 milligrams (mg) MAM01 subcutaneously (SC)

EXPERIMENTAL

Participants will receive MAM01.

Drug: MAM01 300 mg SC

Part A: Cohort 1b (Healthy Adults): 300 mg MAM01 intramuscularly (IM)

EXPERIMENTAL

Participants will receive MAM01.

Drug: MAM01 300 mg IM

Part A: Cohort 1c (Healthy Adults): 2000 mg MAM01 intravenously (IV)

EXPERIMENTAL

Participants will receive MAM01.

Drug: MAM01 2000 mg IV

Part B: Cohort 2a (Healthy Younger Children): 190 mg MAM01 or placebo SC

EXPERIMENTAL

Participants will be randomized in 3:1 ratio (MAM01 : PBO)

Drug: MAM01 190 mg SC; Drug: Placebo SC

Part B: Cohort 2b (Healthy Younger Children): 225 mg MAM01 or placebo SC

EXPERIMENTAL

Participants will be randomized in 3:1 ratio (MAM01 : PBO)

Drug: MAM01 225 mg SC; Drug: Placebo SC

Part B: Cohort 3a (Healthy Infants): 150 mg MAM01 or placebo SC

EXPERIMENTAL

Participants will be randomized in 3:1 ratio (MAM01 : PBO)

Drug: MAM01 150 mg SC; Drug: Placebo SC

Part B: Cohort 3b (Healthy Infants): 150 mg MAM01 or placebo IM

EXPERIMENTAL

Participants will be randomized in 3:1 ratio (MAM01 : PBO)

Drug: MAM01 150 mg IM; Drug: Placebo IM

Part B: Cohort 3c (Healthy Infants): 150 mg MAM01 or placebo IV

EXPERIMENTAL

Participants will be randomized in 3:1 ratio (MAM01 : PBO)

Drug: MAM01 150 mg IV; Drug: Placebo IV

Part B: Cohort 4a (Healthy Infants): 150 mg MAM01 or placebo SC

EXPERIMENTAL

Participants will be randomized in 3:1 ratio (MAM01 : PBO)

Drug: MAM01 150 mg SC; Drug: Placebo SC

Part B: Cohort 4b (Healthy Infants): 150 mg MAM01 or placebo IM

EXPERIMENTAL

Participants will be randomized in 3:1 ratio (MAM01 : PBO)

Drug: MAM01 150 mg IM; Drug: Placebo IM

Part B: Cohort 4c (Healthy Infants): 150 mg MAM01 or placebo IV

EXPERIMENTAL

Participants will be randomized in 3:1 ratio (MAM01: PBO)

Drug: MAM01 150 mg IV; Drug: Placebo IV

Interventions

MAM01 300 mg SC DRUG

MAM01 300 mg will be administered SC

Part A: Cohort 1a (Healthy Adults): 300 milligrams (mg) MAM01 subcutaneously (SC)

MAM01 300 mg IM DRUG

MAM01 300 mg will be administered IM route

Part A: Cohort 1b (Healthy Adults): 300 mg MAM01 intramuscularly (IM)

MAM01 2000 mg IV DRUG

MAM01 2000 mg will be administered IV

Part A: Cohort 1c (Healthy Adults): 2000 mg MAM01 intravenously (IV)

MAM01 190 mg SC DRUG

MAM01 190 mg will be administered SC

Part B: Cohort 2a (Healthy Younger Children): 190 mg MAM01 or placebo SC

MAM01 225 mg SC DRUG

MAM01 225 mg will be administered SC

Part B: Cohort 2b (Healthy Younger Children): 225 mg MAM01 or placebo SC

MAM01 150 mg SC DRUG

MAM01 150 mg will be administered SC

Part B: Cohort 3a (Healthy Infants): 150 mg MAM01 or placebo SC; Part B: Cohort 4a (Healthy Infants): 150 mg MAM01 or placebo SC

MAM01 150 mg IM DRUG

MAM01 150 mg will be administered IM

Part B: Cohort 3b (Healthy Infants): 150 mg MAM01 or placebo IM; Part B: Cohort 4b (Healthy Infants): 150 mg MAM01 or placebo IM

MAM01 150 mg IV DRUG

MAM01 150 mg will be administered IV

Part B: Cohort 3c (Healthy Infants): 150 mg MAM01 or placebo IV; Part B: Cohort 4c (Healthy Infants): 150 mg MAM01 or placebo IV

Placebo SC DRUG

Placebo will be administered SC

Part B: Cohort 2a (Healthy Younger Children): 190 mg MAM01 or placebo SC; Part B: Cohort 2b (Healthy Younger Children): 225 mg MAM01 or placebo SC; Part B: Cohort 3a (Healthy Infants): 150 mg MAM01 or placebo SC; Part B: Cohort 4a (Healthy Infants): 150 mg MAM01 or placebo SC

Placebo IV DRUG

Placebo will be administered IV.

Part B: Cohort 3c (Healthy Infants): 150 mg MAM01 or placebo IV; Part B: Cohort 4c (Healthy Infants): 150 mg MAM01 or placebo IV

Placebo IM DRUG

Placebo will be administered IM

Part B: Cohort 3b (Healthy Infants): 150 mg MAM01 or placebo IM; Part B: Cohort 4b (Healthy Infants): 150 mg MAM01 or placebo IM

Eligibility Criteria

• Age: 3 Months - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• PART A
• Male or female adults aged 18 to 55 years inclusive at the time of signing the informed consent form (ICF), who are capable of, and willing to provide, informed consent
• Healthy, as determined by Investigator assessment, including medical history, physical examination, and screening laboratory results
• All dosing groups: hemoglobin level ≥ 8 grams per deciliter (g/dL)
• All dosing groups: living within local jurisdiction of trial site(s) and available for the duration of the trial for all cohorts
• Female participants of childbearing potential must be nonpregnant and agree to avoid becoming pregnant by using an acceptable contraception method
• PART B
• Age Cohort 2: male or female children aged 2 years to \<5 years at the time their parent or Legally Authorized Representative (LAR) signs the ICF
• Age Cohort 3: male or female children aged 12 months to \<24 months at the time their parent or LAR signs the ICF
• Age Cohort 4: male or female infant children aged 3 months to \<12 months and weighing at least 5 kilograms (kg) at the time their parent or LAR signs the ICF
• Healthy, as determined by Investigator assessment, including medical history, physical examination, and screening laboratory results
• Hemoglobin level ≥ 8g/dL
• Height and weight Z-scores ≥-2
• Living within local jurisdiction of trial site(s) and available for the duration of the trial

You may not qualify if:

• PART A \& PART B
• Within 48 hours prior to randomization, acute febrile illness
• Sickle cell disease or history of splenectomy
• Use of antimalarial chemoprevention or treatment, and/or antibiotics with known antimalarial effects (eg, clotrimoxazole, azithromycin, tetracyclines) within 30 days prior to dosing
• Enrolled in another clinical trial within 90 days prior to Screening or planning to participate in another trial during, or within 1 year following, their participation in this trial
• Received any doses of a malaria vaccine or other monoclonal antibodies (mAb) to Pf
• Eligible to receive a malaria vaccine (RTS, S/AS01 or R21/Matrix-M) at screening or if it is expected to become available during the period of the trial.
• History of allergy or hypersensitivity or contraindications to trial drugs (including those used as empirically treatment for Pf to clear any existing parasitemia), excipients or related substances
• Any history of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the trial
• History of any autoimmune disease or immunodeficiency or other impairment to the immune system, including HIV infection
• Use of chronic (≥ 14 days) immunosuppressive agents including systemic steroids (eg, prednisone \>10 milligrams per day \[mg/day\]) within 30 days prior to dosing. Use of inhaled or topical corticosteroids is permitted
• Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising with blood draws
• Receipt of immunoglobulins and/or blood products within the past 6 months
• Any current uncontrolled medical or psychiatric condition, or substance abuse problems that in the opinion of the Investigator, will make it unlikely for participant to comply with the protocol, may interfere with study assessments, or could jeopardize the safety of the participant
• Any contraindication for a subcutaneous injection, intravenous injection, or intramuscular injection, as applicable

Sponsors & Collaborators

• Gates Medical Research Institute: lead

Study Sites (2)

JCRC-Joint Clinical Research Centre

Kampala, 10005, Uganda

RECRUITING

IDRC-Infectious Disease Research Collaboration, IDRC Tororo Hospital Station Road

Tororo, 749, Uganda

RECRUITING

MeSH Terms

Conditions

Malaria; Malaria, Falciparum

Condition Hierarchy (Ancestors)

Protozoan Infections; Parasitic Diseases; Infections; Mosquito-Borne Diseases; Vector Borne Diseases

Central Study Contacts

Gates MRI

CONTACT

+1 866 789 5767; clinical.trials@gatesmri.org

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Part A: Open Label. Part B: Double Blind
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 7, 2024
• First Posted: May 10, 2024
• Study Start: March 28, 2025
• Primary Completion: January 1, 2026
• Study Completion: January 1, 2026
• Last Updated: August 26, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
• Time Frame: Within 12 months of the study completion date
• Access Criteria: Anonymized participant-level data may be shared with external researchers in accordance with trial participants' written and executed informed consent and applicable local regulations. Qualified researchers may submit a request along with a research proposal to Gates MRI for review. A data sharing agreement must be in place before any clinical trial data are shared. Additional restrictions may apply due to contractual obligations or regulatory constraints.

Locations

UG (2)